How does Myriad conduct BART testing?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
The so-called racial gap in breast cancer care has long been suggested by researchers, with black and Hispanic women less likely to get recommended breast cancer treatments than white patients. Researchers claim financial factors such as economic and social class or access to insurance alone can't e....
Because they are derived from normal cells that have hormone receptors and the normal cells must respond to hormones in order to fulfil their function. A high proportion of breast cancers are Estrogen Receptor Positive. This means they have a large number of estrogen receptors, indicating that estro....
A number of masses can be found within the female breast but not all of them are cancerous. So, don’t panic if you find a mass. Among the benign masses, most are only an inconvenience and have no threat, but some may be associated with increased long-term risk of breast cancer. A fibroadenoma is a ....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
எழுதியவர்:Dr. Nitika Sharma - BDS
மதிப்பிட்டவர்:Dr. Rakesh Kumar - MBBS, MS
Mahima Chaudhary
Imagine going in for a cancer screening, and the technician turns to you and says, "We're finished, but if I push this button over here, the machine can detect even smaller cancers. But here's the hitch: You have to pay $700 if you want me to push this button."
Myriad Genetics is doing something very similar with BART tests that determine if a woman has a potentially dangerous genetic abnormality linked to breast cancers.
When testing shows that a woman carries a bad gene, she has a much higher chance of getting breast cancer. These women usually then get more frequent MRIs, ultrasounds and mammograms to detect cancer.
Myriad owns the patent on breast cancer genes and so is the only company that can test for them. It offers one test that catches most, but not all, abnormalities, and then charges nearly all patients $700 for a second test that catches the rest.
If a woman can't afford the $700 fee, she may miss an abnormality, which could mean the difference between life and death.
Myriad defends the $700 charge for its second test, called BART, even though many patients can't afford it and insurance won't pay for it.